6975-91-3

Usage

Uses

Used in Pharmaceutical Industry:
CYCLOHEXYL 2-CHLOROACETATE is used as an intermediate in the synthesis of pharmaceuticals for its ability to participate in various chemical reactions, contributing to the development of new medications.
Used in Agrochemical Industry:
In the agrochemical sector, CYCLOHEXYL 2-CHLOROACETATE is utilized as a reagent in the production of agrochemicals, aiding in the creation of substances that protect crops and enhance agricultural productivity.
Used in Fragrance Industry:
CYCLOHEXYL 2-CHLOROACETATE is employed as a component in the synthesis of fragrances, leveraging its chemical properties to create a variety of scent compounds used in perfumes and other aromatic products.
Used in Chemical Production:
CYCLOHEXYL 2-CHLOROACETATE is used as an intermediate in the production of other chemicals such as plasticizers, which are additives improving the flexibility of plastics, and pesticides, crucial for controlling pests in various settings.
Used in Coating Industry:
CYCLOHEXYL 2-CHLOROACETATE is also utilized in the formulation of coatings, where its chemical properties contribute to the development of high-quality and durable products for various applications.

InChI:InChI=1/C8H13ClO2/c9-6-8(10)11-7-4-2-1-3-5-7/h7H,1-6H2

Upstream product

• 79-11-8 chloroacetic acid 
• 108-93-0 cyclohexanol 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 75549-93-8 N,N-diethyl-glycine cyclohexyl ester 
• 22500-00-1 β-Cyan-β-phenyl-propionsaeure-cyclohexylester 
• 22500-03-4 β-Cyan-β-phenyl-glutarsaeure-di-cyclohexylester 
• 103717-33-5 (Dibutoxy-phosphoryl)-acetic acid cyclohexyl ester 
• 103717-29-9 (Diisopropoxy-phosphoryl)-acetic acid cyclohexyl ester 
• 103717-37-9 [Bis-(2-ethyl-hexyloxy)-phosphoryl]-acetic acid cyclohexyl ester 
• 114653-17-7 cyclohexylacetyl 4-hydroxyphenylacetate 
• 114703-78-5 cyclohexyl azidoacetate 
• 65717-27-3 cyclohexyl 2-(diethoxyphosphoryl)acetate 
• 25344-92-7 C₃₀H₅₈N₂O₄⁽²⁺⁾*2Cl^(1-) 
• 114703-79-6 2-(cyclohexyloxy)-2-oxoethan-1-aminium chloride 
• 114703-83-2 N-cyclohexyl-N-methyl-4-[2-amino-3-(cyclohexyloxycarbonylmethyl)-3,4-dihydroquinazolin-6-yl]oxybutyramide hydrobromide 
• 1366067-97-1 3-tert-butoxycarbonylaminopropionic acid cyclohexyloxycarbonylmethyl ester 

Relevant academic research and scientific papers

(meth)acrylate compound

The invention relates to a (meth)acrylate compound as well as a preparation method and application thereof. The compound has the following structure shown in the specification, and the preparation method is simple. The compound has the advantages of low odor or no odor, low irritation or no irritation, low viscosity, high reactivity and moderate glass transition temperature of the obtained polymer, can participate in free radical polymerization, has favorable flexibility and adhesivity, and can be used in light-cured ink, paint and adhesives.

New Diesters Derived from Piperine: In silico Study and Evaluation of Their Antimicrobial Potential

Piperine, previously extracted from black pepper (Piper nigrum L.), was used as a precursor for the synthesis of twelve new diester derivatives. The final products were obtained through the bimolecular nucleophilic substitution reaction (SN2) of the alkyl 2-chloroacetates and the salt of piperic acid, obtained from the basic hydrolysis of piperine. The compounds were synthesized with yields of 55-84% and characterized by infrared spectroscopy and 1H and 13C nuclear magnetic resonance. The evaluation of the compounds’ potential as new drug candidates was done through an in silico study of ADME properties (absorption, distribution, metabolization and excretion) and evaluation of antimicrobial activity against bacterial strains (Staphylococcus aureus and Pseudomonas aeruginosa), yeasts (Candida albicans and Candida tropicalis) and filamentous fungi (Aspergillus fumigatus, Aspergillus flavus and Aspergillus niger). The in silico study showed that the compounds were good drug candidates and antimicrobial evaluation demonstrated that 9 of the 12 compounds exhibited a minimum inhibitory concentration (MIC) ranging 1024-256 μg mL?1

Electronic and steric substituent influences on the conformational equilibria of cyclohexyl esters: The anomeric effect is not anomalous!

The cyclohexyl esters of a series of carboxylic acids, RCO2H, spanning a range of electronegativities and quotients of steric hindrance for the R substituent (R = Me, Et, iPr, tBu, CF3, CH2Cl, CHCl2, CH2Br, CHBr2, and CBr3) were prepared. Their conformational equilibria in CD2Cl2 were examined by low-temperature 1H NMR spectroscopy to study the axial or equatorial orientation of the ester functionality with respect to the adopted chair conformation of the cyclohexane ring. The ab initio and DFT geometry-optimized structures and relative free energies of the axial and equatorial conformers were also calculated at the HF/ 6-311G**, MP2/6-311G, and B3LYP/ 6-31G** levels of theory, both in the gas phase and in solution. In the latter case, a self-consistent isodensity polarized continuum model was employed. Only by including electron correlation in the modeling calculations for the solvated molecules was it possible to obtain a reasonable correlation between ΔG°calcd and ΔG°exp. Both the structures and the free energy differences of the axial and equatorial conformers were evaluated with respect to the factors normally influencing conformational preference, namely, 1,3-diaxial steric interactions in the axial conformer and hyperconjugation. It was assessed that hyperconjugative interactions, σC-C/σC-H and σC-O*, together with a steric effect - the destabilization of the equatorial conformer with increasing bulk of the R group - were the determinant factors for the position of the conformational equilibria. Thus, because hyperconjugation is held responsible as the mitigating factor for the anomeric effect in 2-substituted, six-membered saturated heterocyclic rings, and since it is also similarly responsible, at least partly, in these monosubstituted cyclohexanes for a preferential shift towards the axial conformer, the question is therefore raised: can the anomeric effect really be construed as anomalous?

Microwave-assisted preparation of benzo[b]furans under solventless phase-transfer catalytic conditions

Condensation of salicylaldehyde and its derivatives with various esters of chloroacetic acids in the presence of tetrabutylammonium bromide (TBAB) leads to the synthesis of benzo[b]furans by a solventless phase-transfer catalytic (PTC) reaction under microwave irradiation. (C) 2000 Elsevier Science Ltd.

N-N-DISUBSTITUTED-OMEGA-(2-AMINO-3-(CARBONYLMETHYL)-3,4-DIHYDROQUINAZOLINYL)OXY-ALKYLAMIDES AND RELATED COMPOUNDS

Compounds are disclosed according to the formula or an optical isomer thereof. The compounds of formula I are cyclic AMP phosphodiesterase inhibitors useful as antithrombotic and inotropic agents and the like in mammals

Inhibitors of Cyclic AMP Phosphodiesterase. 4. Synthesis and Evaluation of Potential Prodrugs of Lixazinone (N-Cyclohexyl-N-methyl-4quinazolin-7-yl)oxy>butyramide, RS-82856)

The cyclic AMP phosphodiesterase (cAMP PDE) inhibitor and cardiotonic agent lixazinone (N-cyclohexyl-N-methyl-4-quinazolin-7-yl)oxy>butyramide, RS-82856, 1) and its acid and base addition salts were found to be insufficiently soluble in formulations suitable for intravenous administration.These results prompted an investigation into potential prodrugs with enhanced aqueous solubility designed to deliver 1 by three distinct mechanisms: (1) decarboxylation of α-carboxamides; (2) hydrolytic loss of a solubilizing N-1-(acyloxy)methyl or (N,N-dialkylamino)methyl moiety; or (3) intramolecular closure of a guanidino ester or amide.The target compounds were evaluated as delivery systems for 1 by three criteria: (1) chemical conversion rate to 1 under physiological conditions; (2) inhibition of type IV cAMP PDE at a fixed time point; and (3) in vivo inotropic activity in anesthetized dogs by both intravenous and oral administration.Release of 1 from 4a (series 1) was found to be too slow to be of value as prodrug of 1, since decarboxylation could be induced only by strong acid, conditions under which hydrolytic ring opening was found to severely compete.Conversely, 1 was released too readily on exposure of (N,N-dialkylamino)methyl derivatives such as 8d (series 2) to physiological conditions, although no large increase in aqueous solubility was realized.Finally, both the physicochemical and in vitro studies indicated that ring closure of the guanidinium esters and amides 17a-k (series 3) to 1 was quantitative and pH- and time-dependent, suggesting the possibility of delivery of the open, water-soluble prodrug form, followed by closure to 1 in plasma.Detailed examination of these agents in vivo, however, demonstrated that only those compounds that rapidly cyclized to 1, as measured by plasma levels of 1, exhibited inotropic activity, indicating that the open prodrug form was not efficiently absorbed upon oral administration.

Soft Drugs. 7. Soft β-Blockers for Systemic and Ophthalmic Use

The "inactive metabolite approach" used to design a series of "soft" drugs derived from the acidic metabolite of metoprolol.Pharmacokinetic and pharmacodynamic properties of these novel "soft" β-adrenoceptor antagonists were determined: half-lives in human blood ranged from 5 to 754 min.The rates of in vivo disappearance of representative slow, medium, and fast hydrolyzing esters were determined in rats.In each case rapid and quantitative conversion to the corresponding free acid was observed.This suggests a facile, one-step degradation to the predicted major metabolite.The compounds were tested for their ability to decrease intraocular pressure in a rabbit model.Five of the new compounds exerted an ocular hypotensive action comparable to or greater than of the reference compound, timolol maleate, and with a prolonged duration of action in some cases.In contrast the new compounds showed reduced and shorter duration systemic activity.The adamantylethyl ester emerges as a potentially effective antiglaucoma agent with significantly improved site-specific activity.